Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IHH Healthcare Berhad (5225.KL)
Kuala Lumpur, MY
IHH Healthcare Berhad, established in Kuala Lumpur, Malaysia, in 2010, functions as a global investment holding company renowned for its comprehensive healthcare services. Its expansive operational footprint stretches across Malaysia, Singapore, Turkey, India, China, Japan, Europe, and other international markets. The company delivers a full spectrum of patient care, starting with primary services like routine check-ups, vaccinations, and treatment for common illnesses, and progressing to secondary care encompassing specialist consultations, minor surgeries, and emergency medical attention. It further provides advanced tertiary care, which includes specialized consultations, complex medical treatments, and inpatient services, alongside highly specialized quaternary care, featuring organ transplantation, neurosurgery, intricate cardiac procedures, and reconstructive plastic surgery. Beyond direct patient treatment, IHH Healthcare provides a wide array of supporting and operational services. These include advanced diagnostics, analytical laboratory testing, therapeutic radiology, and integrated rehabilitation, as well as advanced molecular diagnostics. The company is also a significant player in medical education, actively training nurses, doctors, and allied healthcare professionals. Its diverse operations extend to administrative, management, and consultancy services, various emergency and home care offerings (including orthopedic and ambulatory care), and the development of healthcare information systems and technology solutions. Furthermore, IHH Healthcare manages real estate investment trusts, operates specialized centers such as dialysis and treasury facilities, and establishes educational institutions for medical learning and research. It oversees the entire lifecycle of healthcare infrastructure, from developing and constructing facilities to their supervision, management, and leasing. Complementary services like hospital catering, laundry, and cleaning, alongside the import and wholesale of pharmaceuticals and medical materials, are also integral to its vast business portfolio. The company additionally engages in property letting and provides software system integration and application management services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.56% | +0.00% | +1.82% | -2.08% | +8.51% | +2.06% | +29.42% | +52.91% | +70.75% | +36.75% | +189.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 13 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+5.6% Q1'26: +4.1% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-20.0% Q1'26: +2.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+7.2% Q1'26: +2.6% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+12.9% ★ Q1'26: +18.7% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+5.1% Q1'26: +7.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.2% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×3.34× Q1'26: 2.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 12 EPS Ana. |
Dec 2027 23 Rev. Ana. 20 EPS Ana. |
Dec 2028 14 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.45B
est: 8.54B (-1.0%)
|
10.01B
est: 10.02B (0.0%)
|
11.14B
est: 11.25B (-0.9%)
|
11.52B
est: 11.78B (-2.2%)
|
14.91B
est: 14.51B (+2.7%)
|
13.40B
est: 13.40B (0.0%)
|
17.13B
est: 16.50B (+3.8%)
|
17.99B
est: 17.85B (+0.8%)
|
20.94B
est: 19.87B (+5.4%)
|
24.38B
est: 23.23B (+5.0%)
|
25.75B
est: 25.88B (-0.5%)
|
28.20B
27.57B – 28.74B
+9.0% YoY
|
30.87B
26.93B – 33.28B
+9.5% YoY
|
33.84B
31.22B – 35.52B
+9.6% YoY
|
| EBITDA |
2.07B
est: 2.08B (-0.8%)
|
1.88B
est: 2.44B (-23.0%)
|
2.45B
est: 2.74B (-10.6%)
|
2.00B
est: 2.87B (-30.4%)
|
2.94B
est: 3.54B (-16.9%)
|
2.45B
est: 3.27B (-25.0%)
|
4.31B
est: 4.03B (+7.1%)
|
4.09B
est: 4.35B (-6.1%)
|
6.28B
est: 4.85B (+29.6%)
|
6.28B
est: 5.76B (+8.9%)
|
5.24B
est: 6.42B (-18.4%)
|
6.99B
6.84B – 7.13B
+9.0% YoY
|
7.66B
6.68B – 8.25B
+9.5% YoY
|
8.39B
7.74B – 8.81B
+9.6% YoY
|
| EBIT |
1.38B
est: 1.40B (-1.4%)
|
1.08B
est: 1.64B (-34.0%)
|
1.44B
est: 1.84B (-21.6%)
|
1.04B
est: 1.93B (-46.2%)
|
1.61B
est: 2.37B (-32.3%)
|
1.03B
est: 2.19B (-52.8%)
|
3.00B
est: 2.70B (+11.1%)
|
2.69B
est: 2.92B (-7.8%)
|
4.77B
est: 3.25B (+46.9%)
|
4.54B
est: 4.03B (+12.7%)
|
3.33B
est: 4.49B (-25.9%)
|
4.90B
4.79B – 4.99B
+9.0% YoY
|
5.36B
4.68B – 5.78B
+9.5% YoY
|
5.87B
5.42B – 6.17B
+9.6% YoY
|
| Net Income |
933.90M
est: 1.00B (-6.6%)
|
612.35M
est: 996.08M (-38.5%)
|
969.95M
est: 810.51M (+19.7%)
|
627.69M
est: 772.43M (-18.7%)
|
551.48M
est: 908.85M (-39.3%)
|
199.04M
est: 508.76M (-60.9%)
|
1.86B
est: 1.54B (+21.1%)
|
1.55B
est: 1.51B (+2.2%)
|
2.95B
est: 1.77B (+67.0%)
|
2.66B
est: 1.96B (+35.6%)
|
2.10B
est: 1.94B (+8.1%)
|
2.28B
2.03B – 2.48B
+17.1% YoY
|
2.59B
2.12B – 3.12B
+13.8% YoY
|
3.08B
2.77B – 3.28B
+19.0% YoY
|
| SGA |
1.12B
est: 1.14B (-2.4%)
|
1.43B
est: 1.34B (+6.5%)
|
1.59B
est: 1.51B (+5.5%)
|
1.69B
est: 1.58B (+7.4%)
|
2.01B
est: 1.95B (+3.1%)
|
1.80B
est: 1.80B (-0.1%)
|
2.16B
est: 2.21B (-2.2%)
|
2.56B
est: 2.39B (+7.0%)
|
2.81B
est: 2.66B (+5.5%)
|
3.25B
est: 3.09B (+5.4%)
|
3.30B
est: 3.44B (-4.1%)
|
3.75B
3.66B – 3.82B
+9.0% YoY
|
4.10B
3.58B – 4.42B
+9.5% YoY
|
4.49B
4.15B – 4.72B
+9.6% YoY
|
| EPS |
0.11
est: 0.11 (-3.1%)
|
0.07
est: 0.11 (-34.2%)
|
0.11
est: 0.09 (+19.6%)
|
0.08
est: 0.09 (-13.6%)
|
0.05
est: 0.10 (-48.8%)
|
0.02
est: 0.06 (-60.7%)
|
0.20
est: 0.17 (+14.6%)
|
0.17
est: 0.17 (-1.1%)
|
0.34
est: 0.20 (+69.5%)
|
0.30
est: 0.22 (+35.2%)
|
0.24
est: 0.22 (+9.1%)
|
0.26
0.23 – 0.28
+17.1% YoY
|
0.29
0.24 – 0.35
+13.8% YoY
|
0.35
0.31 – 0.37
+19.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ashok Pandit | Group Chief Corporate Officer | — | male |
| Ashutosh Raghuvanshi | MD & Chief Executive Officer of Fortis Healthcare | — | — |
| Associate Hsiu Chin Lim | Group Chief Medical Officer | — | — |
| Ching Voon Seow | Company Secretary | — | female |
| Chorng Ann Chow | Chief Executive Officer of IHH Healthcare Singapore | — | — |
| Dilip Kadambi | Group Chief Financial Officer | — | male |
| Hing Lim Tsang | Regional Chief Executive Officer of IHH Healthcare North Asia | — | — |
| Ida Suryati binti Ab Rahim | Group General Counsel | — | female |
| Kamal Amzan | Chief Executive Officer of IHH Healthcare Malaysia | — | — |
| Kelvin Chong | Group Treasury, Corporate Finance & Investor Relations | — | male |
| Nili Shayrina binti Saat | Group Chief Risk Officer | — | female |
| Prem Kumar Nair | Group Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 5225.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
